<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921804</url>
  </required_header>
  <id_info>
    <org_study_id>D1960C00004</org_study_id>
    <nct_id>NCT00921804</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients</brief_title>
  <official_title>A Phase IIa, Double-blind, Double-Dummy, Placebo-controlled, Active-controlled, Randomized, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD8529 in Adult Schizophrenia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with daily oral dose of AZD8529
      40 mg administered over 28 days is safe, well tolerated and improves main symptoms of
      schizophrenia in adult schizophrenia patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS Total Score</measure>
    <time_frame>Prior to randomization (screening, admission to washout/run in, baseline) and Days 8, 15, 22, and 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PANSS Positive, Negative, and General Psychopathology Subscale Scores</measure>
    <time_frame>Prior to randomization (screening, admission to washout/run in, baseline) and Days 8, 15, 22, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-S</measure>
    <time_frame>Prior to randomization (screening, admission to washout/run in, baseline) and Days 8, 15, 22, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs measurements, body weight, physical exam, clinical laboratory evaluations, ECGs, Extrapyramidal Symptoms, suicidal symptoms, cognition and incidence of adverse events</measure>
    <time_frame>Prior to randomization (screening, admission to washout/run in, baseline) and Days 1, 8, 15, 22, and 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">296</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD8529 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Risperidone 4 mg (2mg on Day 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD 8529</intervention_name>
    <description>40mg oral daily capsule administered as a single dose in the morning for 28 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match AZD8529</intervention_name>
    <description>Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match risperidone</intervention_name>
    <description>Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient will need to read, understand and sign an informed consent prior to any study
             specific procedures

          -  Patient will have certain schizophrenia symptoms deemed by the investigator as
             appropriate for the study entry

        Exclusion Criteria:

          -  Patients will be excluded based on recent history of significant illness or current
             disease as assessed by the investigator during screening process (based on physical
             examination, laboratory studies and electrocardiogram studies)

          -  Patients will be excluded if urine drug screen test show positive results

          -  Smoking of more than 2 packs of cigarettes a day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert , Litman, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>CBH Health9605 Medical Center Drive Suite 270Rockville, MD, 20850</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Smith</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca1800 Concord PikeWilmington, DE, 19850</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>June 29, 2010</last_update_submitted>
  <last_update_submitted_qc>June 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Hallucinations</keyword>
  <keyword>Paranoia</keyword>
  <keyword>Inpatient schizophrenia clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

